Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Meta-static Breast Cancer Patients Treated within the TANIA Phase III Trial.

Posted bybrigittemeiswinkel

Rinnerthaler, G; Gampenrieder, SP; Hackl, H; Steiner, M; Monzo-Fuentes, C; Melchardt, T; Magnes, T; Huemer, F; Westphal, T; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Greil, R.

J Clin Med. 2020 Jun 1;9(6):1663. doi: 10.3390/jcm9061663.

https://pubmed.ncbi.nlm.nih.gov/32492882/